|POZEN's Dr. William Kelce Appointed Adjunct Associate Professor at UNC, Chapel Hill|
CHAPEL HILL, N.C.--(BUSINESS WIRE)--Feb. 21, 2008--POZEN Inc. (NASDAQ: POZN), today announced that Dr. William R. Kelce, vice president, preclinical and early clinical development, has been appointed adjunct associate professor, Department of Pediatrics, School of Medicine, University of North Carolina, Chapel Hill effective February 1, 2008.
In addition, Dr. Kelce is chairman of the Board of Publications for the journal Toxicological Sciences and on the editorial review boards for the journals Environmental Health Perspectives, Toxicology and Applied Pharmacology, and Birth Defects Research, Developmental and Reproductive Toxicology. Dr. Kelce has been a Fellow of the Academy of Toxicological Sciences since 2000.
POZEN is a pharmaceutical company committed to developing therapeutic advancements for diseases with unmet medical needs where it can improve efficacy, safety, and/or patient convenience. POZEN's efforts are focused primarily on the development of pharmaceutical products for the treatment of acute and chronic pain and other pain-related conditions. POZEN has development and commercialization alliances with GlaxoSmithKline for the proposed product candidate Treximet(TM) which is currently under review by the United States Food and Drug Administration for the acute treatment of migraine, and with AstraZeneca for the proposed product candidate PN 400 for conditions such as osteoarthritis and rheumatoid arthritis in patients who are at risk for developing NSAID-associated gastric ulcers. The company's common stock is traded on The Nasdaq Stock Market under the symbol "POZN". For detailed company information, including copies of this and other press releases, see POZEN's website: www.pozen.com.
CONTACT: POZEN Inc.